Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith M Gottwein

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|September 25, 2013
Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitorJudith M Gottwein, Sanne B Jensen, Stéphanie B N Serre, et al.
Journal of Virology|June 24, 2011
Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5AJudith M Gottwein, Tanja B Jensen, Christian K Mathiesen, et al.
Journal of Hepatology|November 6, 2018
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escapeLong V Pham, Sanne Brun Jensen, Ulrik Fahnøe, et al.
Journal of Virology|March 5, 2010
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studiesJudith M Gottwein, Troels K H Scheel, Benoit Callendret, et al.
Plos One|July 30, 2021
Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigensJannick Prentoe, Christoph M Janitzek, Rodrigo Velázquez-Moctezuma, et al.
Viruses|February 26, 2022
Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and ReplicationUlrik Fahnøe, Long V Pham, Carlota Fernandez-Antunez, et al.
Scientific Reports|July 17, 2021
In vitro efficacy of artemisinin-based treatments against SARS-CoV-2Yuyong Zhou, Kerry Gilmore, Santseharay Ramirez, et al.
Hepatology (Baltimore, Md.)|April 23, 2024
JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralizationLaura Collignon, Kenn Holmbeck, Ashley Just, et al.
Infection and Immunity|March 26, 2003
Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal miceJulia C Eisenberg, Steven J Czinn, Christine A Garhart, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2021
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 <i>In Vitro</i>Karen A Gammeltoft, Yuyong Zhou, Carlos R Duarte Hernandez, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|September 25, 2013
Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitorJudith M Gottwein, Sanne B Jensen, Stéphanie B N Serre, et al.
Journal of Virology|June 24, 2011
Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5AJudith M Gottwein, Tanja B Jensen, Christian K Mathiesen, et al.
Journal of Hepatology|November 6, 2018
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escapeLong V Pham, Sanne Brun Jensen, Ulrik Fahnøe, et al.
Journal of Virology|March 5, 2010
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studiesJudith M Gottwein, Troels K H Scheel, Benoit Callendret, et al.
Plos One|July 30, 2021
Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigensJannick Prentoe, Christoph M Janitzek, Rodrigo Velázquez-Moctezuma, et al.
Viruses|February 26, 2022
Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and ReplicationUlrik Fahnøe, Long V Pham, Carlota Fernandez-Antunez, et al.
Scientific Reports|July 17, 2021
In vitro efficacy of artemisinin-based treatments against SARS-CoV-2Yuyong Zhou, Kerry Gilmore, Santseharay Ramirez, et al.
Hepatology (Baltimore, Md.)|April 23, 2024
JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralizationLaura Collignon, Kenn Holmbeck, Ashley Just, et al.
Infection and Immunity|March 26, 2003
Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal miceJulia C Eisenberg, Steven J Czinn, Christine A Garhart, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2021
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 <i>In Vitro</i>Karen A Gammeltoft, Yuyong Zhou, Carlos R Duarte Hernandez, et al.
Pageof 6